News ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
5.24 ^USD	+2.54%		-15.07%	+4.38%

Mar. 26	North American Morning Briefing : Markets Steady -2-	DJ
Mar. 25	Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating	Mar. 25	MT
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy	Mar. 06	BU
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study	Mar. 05	BU
ImmunityBio Announces Data from A Phase 1 Pilot Study	Mar. 05	CI
ImmunityBio Says Cancer Vaccine Trial Moving to Controlled Phase	Feb. 21	MT
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	Feb. 21	BU
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	Feb. 21	CI
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG	Feb. 05	BU
Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG	Feb. 05	CI
US Equity Markets Close Lower Tuesday Ahead of Fed Meeting Minutes	Jan. 02	MT
Sector Update: Health Care Stocks Gain Late Afternoon	Jan. 02	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Jan. 02	MT
ImmunityBio Secures $320 Million Investment From Oberland Capital	Jan. 02	MT
Sector Update: Health Care	Jan. 02	MT
Top Stories at Midday: US Construction Spending Up 0.4% in November; Avangrid-PNM Resources Deal Terminated; Terreno Realty Sells California Property for $15.9 Million; ImmunityBio Secures $320 Million Investment	Jan. 02	MT
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million	Jan. 02	BU
ImmunityBio, Inc. announced that it has received $9.999194 million in funding	Dec. 28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Summary

Filters